Allspring Global Investments Holdings LLC Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Allspring Global Investments Holdings LLC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 53.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,530 shares of the biopharmaceutical company’s stock after purchasing an additional 8,567 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Amicus Therapeutics were worth $195,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. increased its position in Amicus Therapeutics by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 1,280 shares in the last quarter. Diversified Trust Co boosted its stake in Amicus Therapeutics by 2.2% in the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company’s stock worth $682,000 after buying an additional 1,784 shares during the last quarter. Xponance Inc. boosted its stake in Amicus Therapeutics by 11.9% in the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 2,249 shares during the last quarter. Covestor Ltd boosted its stake in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 2,312 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new stake in Amicus Therapeutics in the 4th quarter worth about $29,000.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. The Goldman Sachs Group decreased their price target on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. UBS Group raised their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Finally, Wall Street Zen lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $16.22.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $6.09 on Friday. The firm has a market capitalization of $1.88 billion, a P/E ratio of -67.66 and a beta of 0.51. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $12.65. The company has a debt-to-equity ratio of 2.02, a current ratio of 3.34 and a quick ratio of 2.47. The business’s 50-day simple moving average is $6.07 and its 200-day simple moving average is $7.79.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.